



For Immediate Release

Dec. 13, 2006

Company Name: Dainippon Sumitomo Pharma Co., Ltd.

President: Kenjiro Miyatake

Stock Exchange Listings: Tokyo, Osaka, Nagoya

Security Code number: 4506

Review of overseas development of Lurasidone (SM-13496),  
an atypical antipsychotic

Dainippon Sumitomo Pharma Co., Ltd (Head Office in Osaka, President: Kenjiro Miyatake, hereafter DSP) has today announced it has decided to succeed the overseas clinical development of Lurasidone (SM-13496), which was discovered by DSP and under clinical development for the treatment of schizophrenia, from Merck & Co., Inc (Head Office in NJ, USA, President and CEO, Richard T. Clark, hereafter Merck). Furthermore, DSP has already started its review of the clinical development program to be continued by DSP in the US and Europe.

The compound was licensed to Merck in June 2005 for exclusive global development rights except Japan, China, Taiwan and Korea and was under development. Merck has decided discontinuation of the development of Lurasidone and returns its rights to DSP. DSP has been considering continuation of the development with cooperation of its overseas subsidiaries.

Lurasidone is in Phase IIb development by DSP in Japan for the treatment of schizophrenia.